Keywords: teaer; AED; antiepileptic drug; AMPA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; EIAED; enzyme-inducing antiepileptic drug; IGE; idiopathic generalised epilepsy; ILAE; International League Against Epilepsy; TEAE; treatment-emergent adverse event; Ant
مقالات ISI teaer (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: teaer; AE; adverse event; AED; antiepileptic drug; AMPA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CBZ; carbamazepine; CYP; cytochrome P450; EIAED; enzyme-inducing antiepileptic drug; LOCF; last observation carried forward; OC; observed case; PB; ph
Keywords: teaer; Bronchodilator agents; Electrocardiography; GFF MDI; Pulmonary disease; Chronic obstructive; Holter monitoring; QT prolongation; AE; adverse event; AV; atrioventricular; BID; twice daily; BMI; body mass index; bpm; beats per minute; CI; confidence interva
Keywords: teaer; AED; antiepileptic drug; AMPA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CDR; Cognitive Drug Research; COWAT; Controlled Oral Word Association; EIAED; enzyme-inducing antiepileptic drug; IGF-1; insulin-like growth factor-1; LGPT; Lafayette Gr
Keywords: teaer; ADT; antidepressant treatment; ANCOVA; analysis of covariance; ATRQ; Massachusetts General Hospital Antidepressant Treatment Response Questionnaire; BMI; body mass index; CGI-I; Clinical Global Impressions - Improvement; DSM-IV-TR; Diagnostic and Statis
Keywords: teaer; ANCOVA; Analysis of covariance; C-CASA; Columbia Classification Algorithm for Suicide Assessment; CGI-I; Clinical Global Impressions - Global Improvement; CGI-S; Clinical Global Impressions - Severity of Illness; CRT; Choice Reaction Time; C-SSRS; Col
Keywords: teaer; COPD; Budesonide; Formoterol fumarate dihydrate; Glycopyrronium; Co-suspension delivery technology; Pharmacokinetic; AE; adverse event; AUC0-â; area under the plasma concentration-time curve from time 0 to infinity; AUC0-12; area under the plasma
Keywords: teaer; 4 years; interleukin 17; ixekizumab; long-term; open-label; psoriasis; BCC; basal cell carcinoma; DLQI; Dermatology Life Quality Index; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IL; interleukin; LOCF; last observation c
Keywords: teaer; The trial was registered under NCT02433834 at; http://www.clinicaltrials.gov; Asthma; Co-suspension delivery technology; Glycopyrronium; Inhaled corticosteroid use; Metered dose inhaler; ACQ-5; Asthma Control Questionnaire-5; AE; adverse event; AUC0-3;
Keywords: teaer; 11BHSD; 11β-hydroxysteroid dehydrogenase; ACTH; adrenocorticotropic hormone; AE; adverse event; ALT; alanine aminotransferase; AUC; area under the curve; BMI; body mass index; CBG; cortisol binding globulin; CL/F; apparent total clearance of the drug fro
Keywords: teaer; Urea cycle disorders; Glycerol phenylbutyrate; Children; Infants; Ammonia; Glutamine; ARG1; arginase 1; ASL; argininosuccinate lyase; ASS; argininosuccinate synthetase; BMI; body mass index; BSA; body surface area; CDC; Centers for Disease Control and Pre
Keywords: teaer; biologic therapy; Crohn's disease; inflammatory bowel disease; interleukin-17 antagonists; ixekizumab; psoriasis; ulcerative colitis; AE; adverse event; CD; Crohn's disease; EPIMAD; Registre Epidemiologique des Maladies de l'Appareil Digestif; IBD; inflam
Keywords: teaer; Sublingual immunotherapy; Allergic rhinitis; Allergic rhinoconjunctivitis; Asthma; Dosing; AadSS; Average adjusted symptom score; Amb a 1-U; Ambrosia artemisiifolia 1-unit; AR; Allergic rhinitis; ARC; Allergic rhinoconjunctivitis; AUN; Allergy unit native
Keywords: teaer; ABL-SC; subcutaneous abaloparatide; ACTIVE; Abaloparatide Comparator Trial In Vertebral Endpoints; ACTIVExtend; extension trial of the Abaloparatide Comparator Trial In Vertebral Endpoints; AE; adverse event; ALN; alendronate; BMD; bone mineral density; F
Keywords: teaer; Allergen challenge; allergen peptides; allergy; allergic rhinoconjunctivitis; allergic rhinitis; environmental exposure unit; epitope; grass; immunotherapy; synthetic peptide immunoregulatory epitope; AE; Adverse events; AIT; Allergen immunotherapy; ARC;
Keywords: teaer; 5-Grass pollen tablet; Grass pollen; Allergic rhinoconjunctivitis; Asthma; Sensitization; Allergy immunotherapy; Allergen-specific immunotherapy; Sublingual immunotherapy; Safety; Clinical trial; AE; Adverse event; ARC; Allergic rhinoconjunctivitis; AIT;
Keywords: teaer; clinical trial; cystic fibrosis; exocrine pancreatic insufficiency; pancreatic enzyme-replacement therapy; BMI; Body mass index; CF; Cystic fibrosis; CFA; Coefficient of fat absorption; CNA; Coefficient of nitrogen absorption; EPI; Exocrine pancreatic ins
Keywords: teaer; ADA; anti-drug antibody; AE; adverse event; CCL18; chemokine (C-C motif) ligand 18; ECL; electrochemiluminescence; ELISA; enzyme-linked immunosorbent assay; ERT; enzyme replacement therapy; GD; Gaucher disease; RIP; radioimmunoprecipitation; TEAE; treatme
Keywords: teaer; AE; adverse event; AED; antiepileptic drug; AV; atrioventricular; CV; cardiovascular; ECG; electrocardiogram; PASS; postauthorization safety study; POS; partial-onset seizures; PTSD; posttraumatic stress disorder; SAE; serious adverse event; SS; safety se
Keywords: teaer; Focal epilepsy; Quality of life; Seizure freedom; Lacosamide; AED; antiepileptic drug; CGIC; Clinical Global Impression of Change; CPS; complex partial seizures; CS; Completer Set; FAS; Full Analysis Set; LOCF; last observation carried forward; MedDRA; Me
Keywords: teaer; Glycated hemoglobin (HbA1c); Body weight; Postprandial plasma glucose (PPG); AE; adverse event; BMI; body mass index; DPP-4; dipeptidyl peptidase-4; FPG; fasting plasma glucose; GI; gastrointestinal; GLP-1; glucagon-like peptide-1; HbA1c; glycated hemoglo
Keywords: teaer; Allergic rhinitis; double-blind; placebo-controlled; sublingual immunotherapy tablets; house dust mite; AAdSS; Average Adjusted Symptom Score; AdSS; Adjusted Symptom Score; AIT; Allergen immunotherapy; AR; Allergic rhinitis; ARMS; Average Rescue Medicatio
Keywords: teaer; %FVC; percent predicted forced vital capacity; 6MWT; six-minute walk test; Ab +; antibody positive; Ab â; antibody negative; AEs; adverse events; CSA; conformation-specific antibody assay; ELISA; enzyme-linked immunosorbent assay; FVC; forced vital ca
Keywords: teaer; albaconazole; dermatophyte; nail fungus; onychomycosis; phase II study; triazole; AE; adverse event; ECG; electrocardiogram; ITT; intent to treat; KOH; potassium hydroxide; PK; pharmacokinetic; PP; per protocol; SAE; serious adverse event; SD; standard de
Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
Keywords: teaer; AMPA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; bid; twice daily; FDA; Food and Drug Administration; OLEx; open-label extension; qam; every morning; qd; once daily; qhs; every night at bedtime; qpm; every evening; SG; secondarily generalized;
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
Keywords: teaer; Aripiprazole once-monthly; Schizophrenia; Maintenance treatment; Quality of life; AE; adverse event; APTS; all-patients-treated set; AOM 400; aripiprazole once-monthly 400Â mg; CGI-S; Clinical Global Impressions-Severity; C-SSRS; Columbia Suicide Severity
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results
Keywords: teaer; prostatic neoplasms; prostate-specific antigen; MDV 3100; bone density; drug related side effects and adverse reactions; ADT; androgen deprivation therapy; AE; adverse event; bALP; bone alkaline phosphate; BMD; bone mineral density; CR; complete response;
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia
Keywords: teaer; ANC; Absolute neutrophil count; AML; Acute myeloid leukemia; BL; Baseline; BM; Bone marrow; CI; Confidence intervals; CMML; Chronic myelomonocytic leukemia; CR; Complete remission; ECOG; Eastern Cooperative Oncology Group; HI; Hematologic improvement; HI-
Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease
Keywords: teaer; Co-suspension delivery technology; Formoterol fumarate dihydrate; Glycopyrronium; Metered dose inhaler; Spacer; Valved holding chamber; AE; adverse event; ANOVA; analysis of variance; AUC0-12; area under the curve from 0 to 12â¯h; BMI; body mass index;
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
Keywords: teaer; immune response; Janus kinase inhibitor; pneumococcal vaccine; T cell; tetanus toxoid; tofacitinib; CI; confidence interval; ELISA; enzyme-linked immunosorbant assay; GMFR; geometric mean fold rise; JAK; Janus kinase; LTE; long-term extension; OPA; opsono
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study
Keywords: teaer; Aripiprazole once-monthly; Long-acting injectable antipsychotic; Maintenance therapy; Bipolar I disorder; AE; adverse event; AIMS; Abnormal Involuntary Movement Scale; AOM 400; aripiprazole once-monthly 400 mg; BARS; Barnes Akathisia Rating Scale; BP-I; b
Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity
Keywords: teaer; botulism; botulinum neurotoxin; Human Botulism Immune Globulin; infant botulism; pentavalent botulinum toxoid; recombinant botulinum vaccine; AEs; adverse events; AUC; area under the plasma concentration-time curve; BIG-IV; Human Botulism Immune Globulin
Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany
Keywords: teaer; AURA; a retrospective noninterventional study to assess the effectiveness of existing anti-vascular endothelial growth factor treatment regimens in patients with wet age-related macular degeneration; COMPASS; study to assess the efficacy of treatment wi
Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures
Keywords: teaer; AE; adverse event; AED; antiepileptic drug; CBZ; carbamazepine; +CBZ; patients who were taking concomitant CBZ; -CBZ; patients who were not taking concomitant CBZ; ESL; eslicarbazepine acetate; FS; focal seizures; LEV; levetiracetam; LCM; lacosamide; LT
Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects
Keywords: teaer; GFF MDI; Chronic obstructive pulmonary disease; Co-suspension delivery technology; LAMA/LABA; Pharmacokinetics; AE; adverse event; AUC0-12; area under the curve from 0 to 12â¯h; AUC0-t; area under the curve from 0 to time of the last measurable plasm
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial
Keywords: teaer; α-adrenergic receptors; β-adrenergic receptors; facial dermatoses; skin abnormalities; vascular skin diseases; vasoconstrictor agents; AE; adverse event; CEA; Clinician Erythema Assessment; CTA; Clinician Telangiectasia Assessment; SSA; Subject Self-Ass
Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent
Keywords: teaer; Chronic obstructive pulmonary disease; Co-suspension delivery technology; ICS/LAMA/LABA; Western; Japanese; Triple fixed-dose combination; AE; adverse event; AUC0-12; area under the plasma concentration-time curve from 0 to 12â¯h; AUC0-â; area un
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Keywords: teaer; anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPASI-1; CIMPASI-2; phase 3 trial; CZP; certolizumab pegol; DLQI; Dermatology Life Quality Index; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index;
Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: a randomized controlled phase 3 trial versus trisulfate
Keywords: teaer; ADR; adenoma detection rate; BBPS; Boston Bowel Preparation Scale; BOCLIR; Bowel Cleansing Impact Review; CL; confidence limit; CRC; colorectal cancer; FAS; full analysis set; GFR; glomerular filtration rate; HCS; Harefield Cleansing Scale; LCL; lower con
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
Keywords: teaer; anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPACT; etanercept; phase 3 trial; CZP; certolizumab pegol; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index; PASI 50; â¥50% reduction in PASI from
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Keywords: teaer; anti-IL-17; anti-IL-17A; anti-IL-17F; bimekizumab; biologic therapy; clear or almost clear skin; dose ranging; efficacy; interleukin 17A; interleukin 17F; PASI90; PASI100; phase 2b; plaque psoriasis; randomized clinical trial; safety; AE; adverse event; I
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease
Keywords: teaer; Combined Remission; Clinical Remission; Anal Fistula; Cell Therapy; CDAI; Crohn's Disease Activity Index; CI; confidence interval; Cx601; allogeneic; expanded; adipose-derived stem cells; IBDQ; inflammatory bowel disease questionnaire; LOCF; last observ
Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia
Keywords: teaer; Cirrhosis; Coagulation; Thrombopoietin Receptor Agonist; Thrombosis; AE; adverse event; AESI; adverse event of special interest; CLD; chronic liver disease; MELD; Model for End-Stage Liver Disease; TEAE; treatment-emergent adverse event;
Bispecific antibodies for cancer therapy: A review
Keywords: teaer; ADCC; antibody-dependent cell-mediated cytotoxicity; AE; adverse events; ALL; acute lymphoblastic leukemia; ALP; alkaline phosphatase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; B-ALL; B-cell acute lymphoblastic leukemia; BiTES; Bi-sp
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers
Keywords: teaer; MEDI8852; Monoclonal antibody; Influenza; Hemagglutinin; ADA; anti-drug antibodies; AUC0-t; area under the concentrationâtime curve from time 0 to last sampling time point; AUCâ; area under the plasma concentrationâtime curve from time 0 to infinity
Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month ex
Keywords: teaer; Glycaemic control; Hypoglycaemia; Insulin glargine; Type 2 diabetes; AE; adverse event; ANCOVA; analysis of covariance; BL; baseline; BMI; body mass index; CI; confidence interval; FPG; fasting plasma glucose; Gla-100; glargine 100; Gla-300; glargine 300;
Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study
Keywords: teaer; AED; antiepileptic drug; CNS; central nervous system; ELDQOL; Epilepsy and Learning Disabilities Quality of Life scale; LGS; Lennox-Gastaut Syndrome; QoL; quality of life; SD; standard deviation; TEAE; treatment-emergent adverse event; VABS-II; Vineland
Lifitegrast for the Treatment of Dry Eye Disease
Keywords: teaer; AE; adverse event; CI; confidence interval; DCS; drop comfort score; DED; dry eye disease; EDS; eye dryness score; ICSS; inferior corneal staining score; ITT; intention-to-treat; ODS; ocular discomfort score; SD; standard deviation; TE; treatment effect;
Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension
Keywords: teaer; AE; adverse event; AED; antiepileptic drug; EEG; electroencephalogram; PGE; primary generalized (genetic) epilepsy; PGTCS; primary generalized tonic-clonic seizure; POS; partial-onset seizure; SD; standard deviation; SW; spike-wave; TEAE; treatment-emerge
The efficacy advantage of evolocumab (AMG 145) dosed at 140Â mg every 2Â weeks versus 420Â mg every 4Â weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
Keywords: teaer; ApoB/ApoA-I; Apolipoprotein B/Apolipoprotein A-I; ALT; Alanine aminotransferase; AST; Aspartate aminotransferase; CI; Confidence interval; CVD; Cardiovascular disease; CHD; Coronary heart disease; AMG 145; Evolocumab; Q2W; Every 2Â weeks; Q4W; Every 4Â we